Zepbound week two: what the early hype gets wrong

What did @eatswitynay actually say?

Not much, clinically speaking, and that's worth noting. The creator says they're on their "second week" of "weight loss shots" and refers to the medication as "Zep bound" (Zepbound), confirming they're using tirzepatide. They walk through an auto-injector demonstration, saying things like "twist it to unlock it" and narrate the injection process. There are no explicit health claims, no promised outcomes, and no dosage details shared. This is essentially a documentation video, not a medical advice video. Give credit where it's due: keeping it personal and procedural is the right call for early-stage GLP-1 content.

The creator also mentions doing a weekly update on a separate main account, suggesting a longer-running series. The transcript is rough and clearly auto-generated, so some words are garbled, but the core content is a real-time injection log from someone in their second week of tirzepatide therapy.

Does the science back this up?

The use of tirzepatide for weight loss is supported by some of the strongest clinical trial data in obesity medicine right now. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed that tirzepatide at the highest dose (15 mg weekly) produced an average weight loss of 20.9% of body weight over 72 weeks in adults with obesity without diabetes. That's not a modest effect. It's a meaningful one.

Tirzepatide works as a dual GIP and GLP-1 receptor agonist, which is mechanistically distinct from semaglutide, the active ingredient in Wegovy and Ozempic. Early weeks of tirzepatide use are typically the lowest-dose titration period, designed to minimize gastrointestinal side effects like nausea, vomiting, and diarrhea. The creator is likely on a starting dose of 2.5 mg weekly, per standard prescribing protocols. Week two is genuinely early, and results at this stage are not representative of eventual outcomes, which is something the creator doesn't overclaim about, to their credit.

What did they get wrong (or right)?

They got the basics right. Zepbound is the FDA-approved brand of tirzepatide specifically indicated for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition. Using the correct brand name matters, particularly given how much confusion exists between compounded tirzepatide and the actual FDA-approved product. The creator does not claim Zepbound will cure anything, does not state a specific dose on camera, and does not recommend anyone else take it. That's a low bar, but a lot of GLP-1 content on TikTok fails to clear it.

The injection technique narration is worth scrutinizing. Saying "put it on this vowel" is likely a transcription error for "put it on this vial" or possibly "put it on this towel," which doesn't raise safety flags. Zepbound uses a single-dose auto-injector pen, so the "twist to unlock" instruction is consistent with actual device operation. Nothing in the technique demonstration appears unsafe based on what's audible.

What should you actually know?

If you're considering tirzepatide for weight loss, week two is not the week to judge your results. Most clinical benefit accrues over months, not days. The SURMOUNT-1 data ran 72 weeks for a reason. GI side effects are most common in the first few weeks at the starting dose, and many people interpret early discomfort as the drug not working. That's not accurate.

Zepbound is a weekly subcutaneous injection, not an oral medication, and it requires a valid prescription from a licensed provider. It is not interchangeable with compounded tirzepatide, which is not FDA-approved and carries different quality and safety considerations. If you're watching videos like this and wondering whether you qualify, a telehealth evaluation with a licensed clinician is the appropriate starting point, not a TikTok comment section.

• Tirzepatide is FDA-approved under Zepbound specifically for weight management, not off-label use of Mounjaro.
• Starting doses are low (2.5 mg weekly) to reduce side effects during the first four weeks.
• Long-term adherence matters more than early-week results, per the SURMOUNT-1 data.